Patents Assigned to Allergan Pharmaceuticals
-
Patent number: 10251885Abstract: The present invention relates generally to antifugal compositions. In an embodiment, the antifungal compositions are effective for application to nails and surrounding skin, and comprise at least one volatile solvent, at least one film forming substance, and at least one pyrimidone derivative of formula I, such as albaconazole. These compositions are capable of treating an infection caused by fungi, such as onychomychosis.Type: GrantFiled: May 27, 2010Date of Patent: April 9, 2019Assignee: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITEDInventors: Jon Lenn, Hans Hofland, Edward Hsia
-
Patent number: 10206882Abstract: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing.Type: GrantFiled: October 2, 2013Date of Patent: February 19, 2019Assignee: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITEDInventors: Giovanni Ortenzi, Marco Marconi, Luigi Mapelli
-
Patent number: 10184121Abstract: Methods for screening pancrelipase for RNA virus contamination comprise removing free viral RNA from the pancrelipase, denaturing any viruses in the pancrelipase to release encapsidated RNA into the pancrelipase milieu, and detecting this released RNA. Removal of free viral RNA may comprise treating pancrelipase with RNase and DNase or precipitating the protein fraction of pancrelipase with a salt that precipitates the protein fraction while leaving nucleic acids such as RNA in solution. Pancrelipase substantially devoid of free nucleic acid is also provided.Type: GrantFiled: June 19, 2015Date of Patent: January 22, 2019Assignee: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITEDInventors: Giovanni Ortenzi, Luigi Ghidorsi
-
Patent number: 10016442Abstract: Pharmaceutical gel compositions containing estrogen for vaginal administration, as well as a method of making the same, are disclosed.Type: GrantFiled: June 16, 2006Date of Patent: July 10, 2018Assignee: Allergan Pharmaceuticals International LimitedInventors: David Woolfson, Karl Malcolm
-
Patent number: 9993424Abstract: The present invention relates to a process for the preparation of an intravaginal matrix drug delivery device. The process comprises the steps of combining at least one therapeutic agent in a therapeutically effective amount with at least one biocompatible elastomeric polymer to form a mix; curing said mix in a mold having a shape of said intravaginal drug delivery device, to form a polymer matrix; and maturing said polymer matrix to form the intravaginal drug delivery device. The maturing step alters the release rate characteristics of a device prepared in accordance with the process of the invention.Type: GrantFiled: March 27, 2003Date of Patent: June 12, 2018Assignee: Allergan Pharmaceuticals International LimitedInventors: Brendan Muldoon, Colin Lorimer, Claire Gilligan
-
Patent number: 9976171Abstract: The invention is directed to a process for measuring the amount of digestive enzymes released from a solid composition in a dissolution medium by fluorescence spectroscopy. The invention is also directed to a combined method for measuring both the dissolution and gastroresistance of a solid compositions comprising pancrelipase.Type: GrantFiled: August 8, 2012Date of Patent: May 22, 2018Assignee: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITEDInventors: Massimo Latino, Luigi Ghidorsi, Giovanni Ortenzi
-
Patent number: 9908682Abstract: Ampoules made of plastics material and containing 0.5 to 5 ml of a pharmaceutical formulation are sealed, together with an oxygen scavenger, within a pouch.Type: GrantFiled: September 3, 2014Date of Patent: March 6, 2018Assignee: Allergan Pharmaceuticals International LimitedInventors: Ian Gardener Cameron McAffer, Peter Ernest Tasko
-
Patent number: 9820946Abstract: A pharmaceutical soft gelatin capsule dosage form that includes (a) a shell that includes gelatin; and (b) a fill that includes at least one active ingredient, one or more polyethylene glycol, and a modified guar gum. The pharmaceutical soft gelatin capsule dosage form maintains its shell integrity (hardness) and fill viscosity after storage.Type: GrantFiled: October 27, 2014Date of Patent: November 21, 2017Assignee: Allergan Pharmaceuticals International LimitedInventors: Brendan Muldoon, Ryan Gerald Loughlin, Gerarde Sweeney, Emma Karen Boyd
-
Patent number: 9795569Abstract: A pharmaceutical soft gelatin capsule dosage form that includes (a) a shell that includes gelatin; and (b) a fill that includes at least one active ingredient, one or more polyethylene glycol, and a modified guar gum. The pharmaceutical soft gelatin capsule dosage form maintains its shell integrity (hardness) and fill viscosity after storage.Type: GrantFiled: March 14, 2014Date of Patent: October 24, 2017Assignee: Allergan Pharmaceuticals International LimitedInventors: Brendan Muldoon, Ryan Gerald Loughlin, Gerarde Sweeney, Emma Karen Boyd
-
Mesalamine pharmaceutical composition with multiple dosage elements for reduced delivery variability
Patent number: 9763887Abstract: A mesalamine pharmaceutical composition with reduced delivery variability for delivery of mesalamine to the colon that includes multiple dosage elements, and each dosage element includes mesalamine and an enteric coating. The enteric coating of each different dosage element differs so the release point of the mesalamine in the GI tract is varied. In one embodiment, a first dosage element releases about 30% to about 60% by weight of the total mesalamine in the composition after 60 minutes at a pH of about 6.6 in an aqueous phosphate buffer using a paddle apparatus 2 with a paddle speed of 100 rpm and a second dosage element releases about 40% to about 70% by weight of the total mesalamine after 60 minutes at a pH of about 7.2 in an aqueous phosphate buffer using a paddle apparatus 2 with a paddle speed of 100 rpm.Type: GrantFiled: March 14, 2014Date of Patent: September 19, 2017Assignee: Allergan Pharmaceuticals International LimitedInventors: Ryan Gerald Loughlin, Stephen McCullagh, Roger Boissonneault -
Patent number: 4790846Abstract: A method of making an intraocular lens including providing a fixation member having a proximal end portion with the proximal end portion including an elongated filament, converting a region of said filament at said proximal end portion from a first configuration into a second configuration which is adapted to provide a mechanical interlock and molding an optic about the proximal end portion of the fixation member to form a mechanical interlock between the second configuration and the optic and to attach the fixation member to the optic.Type: GrantFiled: September 15, 1987Date of Patent: December 13, 1988Assignee: Allergan Pharmaceuticals, Inc.Inventors: F. Richard Christ, Dean K. Pettit, Jeffrey C. Day
-
Patent number: 4743588Abstract: Compositions and methods useful for enhancing the transdermal and transmembrane drug delivery of topical and systemic agents. The compositions and methods comprise the active agent together with an effective amount of certain amides of heterocyclic amines as defined herein as penetration enhancers and topically administering to human or animal skin or other membranes the resulting compositions.Type: GrantFiled: June 13, 1984Date of Patent: May 10, 1988Assignee: Allergan Pharmaceuticals, Inc.Inventors: Dorla Mirejovsky, Harun Takruri
-
Patent number: 4670178Abstract: A one step method for cleaning and disinfecting contact lenses is accomplished by immersing the lenses in a solution containing peroxide and a peroxide-active enzyme.Type: GrantFiled: September 9, 1985Date of Patent: June 2, 1987Assignee: Allergan Pharmaceuticals, Inc.Inventors: Stanley W. Huth, Sam W. Lam, Richard M. Kiral
-
Patent number: 4524063Abstract: A topical lodoxamide composition having enhanced efficacy for treatment of ocular allergic diseases. The composition comprises the addition of polyvinyl alcohol to an aqueous solution containing lodoxamide tromethamine.Type: GrantFiled: December 22, 1983Date of Patent: June 18, 1985Assignee: Allergan Pharmaceuticals, Inc.Inventor: Larry A. Wheeler
-
Patent number: 4460573Abstract: A method of preparing solutions containing thimerosal and polyvinylpyrrolidone which results in improved stability of thimerosal is disclosed. The method involves applying a certain amount of heat to the polyvinylpyrrolidone while it is in aqueous solution and prior to its combination with thimerosal. The required thermal input to the polyvinylpyrrolidone solution is a function of four variables: solution temperature, heating time, external pressure and polyvinylpyrrolidone concentration. Advantageously this method may be employed in the manufacture of contact lens solutions.Type: GrantFiled: June 22, 1983Date of Patent: July 17, 1984Assignee: Allergan Pharmaceuticals, Inc.Inventors: Stanley W. Huth, Hali G. Wagner
-
Patent number: 4395346Abstract: A method and composition for the treatment of contact lenses, and especially soft contact lenses such as silicone and hydrophilic plastic contact lenses to remove inorganic deposits. The method consists of treating a contact lens with an aqueous solution containing an effective amount of a sequestering agent, such as a polymetaphosphate, gluconic acid or salts thereof. A preferred polymetaphosphate is sodium hexametaphosphate.Type: GrantFiled: November 18, 1981Date of Patent: July 26, 1983Assignee: Allergan Pharmaceuticals, Inc.Inventor: Frederick D. Kleist
-
Patent number: 4255419Abstract: Low serum zinc concentrations in humans have been associated with multiple sclerosis in some patients, particularly those patients under 50 years of age. Increasing the concentration of serum zinc in such patients has been found to lower the number of, or decrease the severity of recurrent attacks and/or improve neurologic function in some patients.Type: GrantFiled: September 27, 1979Date of Patent: March 10, 1981Assignee: Allergan Pharmaceuticals, Inc.Inventor: Irving H. Leopold
-
Patent number: 4244948Abstract: A method for topically treating inflammation in humans or animals by administering to the inflamed area a therapeutically effective amount of an alkyl- or aralkyl-substituted acetylsalicylic acid such as methyl-, ethyl-, allyl- or benzyl acetylsalicylate. The method may also be used to treat acne by applying a therapeutically effective amount of the acetylsalicylate ester to the affected skin in a human having skin affected by acne.Type: GrantFiled: May 7, 1979Date of Patent: January 13, 1981Assignee: Allergan Pharmaceuticals, Inc.Inventors: Malcolm P. Boghosian, Robert T. Koda
-
Patent number: 4230724Abstract: A method of treating vascularization of the eye as a result of traumatic injury, surgery, such as, corneal transplant, or onset of diabetic retinopathy by topically treating the eye with Flurbiprofen or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 16, 1979Date of Patent: October 28, 1980Assignee: Allergan Pharmaceuticals, Inc.Inventors: Charles A. Cooper, Michael V. W. Bergamini
-
Patent number: D279357Type: GrantFiled: May 20, 1983Date of Patent: June 25, 1985Assignee: Allergan Pharmaceuticals, Inc.Inventor: David W. Mitchell